Uncategorized

Q32 bounces back to claim study success for alopecia drug

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations. 

​Read More

Published

on

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations. 

​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version